ARDX Chief Patient Officer Laura Williams Sells $491K of Stock
Ardelyx's Chief Patient Officer sold 31,000 shares on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Laura Williams, Chief Patient Officer at Ardelyx, Inc. ($ARDX), sold 81,898 shares at an average price of $5.99, worth about $490,569.02, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $ARDX is up 0.2% after 1 week, down 15.9% after 1 month and down 48.9% to date (from the $6.05 close on Jun 18, 2026).
ARDX
Ardelyx, Inc.
Key Points
- Laura Williams, Chief Patient Officer at Ardelyx, sold 31,000 shares on June 18, 2026, with the stock trading at $6.05.
- Ardelyx has a market cap of $1.49 billion and a forward P/E of 11.75, with a 52-week range from $3.49 to $8.40.
- Ladenburg Thalmann assumed coverage with a 'buy' rating and a $16 target, while the consensus remains a strong buy with a $16.30 average target.
Get $ARDX trade alerts by text
We text you when insiders, Congress or big funds trade $ARDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ardelyx, Inc. alert may contain errors. Disclosures
Laura Williams, the Chief Patient Officer at Ardelyx, Inc., sold 31,000 shares of the company on June 18, 2026. This transaction was not part of a pre-planned trading arrangement. Shares of Ardelyx, traded on the NasdaqGM under the ticker ARDX, were priced at $6.05 on the day of the sale.
Ardelyx, Inc. Stock Up 86.3%
On Tuesday, Ardelyx's stock was trading near $6.05. The company, which operates in the biotechnology sector, has a market capitalization of about $1.49 billion. Ardelyx's forward P/E ratio stands at 11.75, indicating its projected earnings relative to its current share price. The stock has a beta of 0.576, suggesting it is less volatile than the market. Over the past year, its share price has ranged from $3.49 to $8.40, and it has 50-day and 200-day moving averages of $6.15 and $6.12, respectively.
Insider Buying and Selling at Ardelyx, Inc.
In addition to Williams's recent sale, she also conducted another transaction on the same day, selling 81,898 shares at an average price of $5.99 under a pre-planned arrangement. Other notable insider activities include purchases by William Bertrand Jr., Richard Rodgers, and Merdad Parsey, who collectively bought over 100,000 shares on June 16, 2026.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage of Ardelyx with a 'buy' rating and a price target of $16. This aligns with the overall strong buy consensus from analysts, who have set an average target price of $16.30. Other firms like HC Wainwright & Co. and Wedbush have maintained 'buy' ratings with targets of $18 and $19, respectively.
About Ardelyx, Inc.
Ardelyx, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on discovering, developing, and commercializing treatments for unmet medical needs. The company offers IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for managing serum phosphorus levels in adults with chronic kidney disease on dialysis. Led by CEO Michael G. Raab, Ardelyx employs 489 people.
Bottom Line
Laura Williams's recent sale of Ardelyx shares highlights ongoing insider activity at the company. Investors often track such transactions as part of their due diligence process. With its stock trading in a volatile range and analysts maintaining a strong buy consensus, Ardelyx remains a company of interest in the biotechnology sector.
Related Filing Alerts
Source: Laura Williams's Form 4 filing on $ARDX (Jun 18, 2026). Find the original filing: ARDX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts